WO2018198101A2 - Procédé de préparation d'une forme cristalline d'éluxadoline - Google Patents

Procédé de préparation d'une forme cristalline d'éluxadoline Download PDF

Info

Publication number
WO2018198101A2
WO2018198101A2 PCT/IB2018/053134 IB2018053134W WO2018198101A2 WO 2018198101 A2 WO2018198101 A2 WO 2018198101A2 IB 2018053134 W IB2018053134 W IB 2018053134W WO 2018198101 A2 WO2018198101 A2 WO 2018198101A2
Authority
WO
WIPO (PCT)
Prior art keywords
eluxadoline
crystalline form
reaction mass
xrpd
depicted
Prior art date
Application number
PCT/IB2018/053134
Other languages
English (en)
Other versions
WO2018198101A3 (fr
Inventor
Sriram Hari MOHAN
Mukesh Kumar Madhra
Ketan Vithalbhai HIRPARA
Original Assignee
Sun Pharmaceutical Industries Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceutical Industries Limited filed Critical Sun Pharmaceutical Industries Limited
Publication of WO2018198101A2 publication Critical patent/WO2018198101A2/fr
Publication of WO2018198101A3 publication Critical patent/WO2018198101A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals

Definitions

  • the present invention relates to processes for the preparation of a crystalline form of eluxadoline.
  • Eluxadoline chemically is 5-[[[(25)-2-amino-3-[4-(aminocarbonyl)-2, 6- dimethylphenyl] - 1 -oxopropyl] [( 15)- 1 -(4-phenyl- lH-imidazol-2-yl)ethyl] amino] methyl] -2- methoxybenzoic acid, represented by Formula I.
  • Eluxadoline is a mu-opioid receptor agonist, indicated in adults for the treatment of irritable bowel syndrome with diarrhea (IBS-D).
  • U.S. Patent No. 7,741 ,356 describes a process for the preparation of eluxadoline.
  • U.S. Patent Nos. 7,629,488 and 8,710,256 describe processes for the preparation of intermediates of eluxadoline.
  • PCT Publication No. WO2009/009480 purportedly discloses forms alpha and beta crystals of eluxadoline and processes thereof.
  • PCT Publication No. WO2009/009480 discloses that form alpha crystals can be prepared by storing the zwitterion of eluxadoline at 0-25% relative humidity (RH) for 3 days and form beta crystals can be prepared by storing the zwitterion of eluxadoline at greater than 60% RH for 3 days.
  • RH relative humidity
  • PCT Publication No. WO2017/015606 purportedly discloses amorphous form, crystalline forms I, II, III and IV, and processes for their preparation and a process for the preparation of form alpha crystal of eluxadoline. Summary of the Invention
  • the present invention relates to processes for the preparation of a crystalline form of eluxadoline.
  • Figure 1 depicts an X-Ray Powder Diffraction (XRPD) pattern of a crystalline form of eluxadoline.
  • Figure 2 depicts an X-Ray Powder Diffraction (XRPD) pattern of a crystalline form of eluxadoline.
  • XRPD X-Ray Powder Diffraction
  • room temperature refers to the temperature in the range of 25°C to 35°C.
  • contacting refers to dissolving, slurrying, stirring, heating, suspending, or combinations thereof.
  • reaction mass refers to suspension, solution, emulsion, or precipitate.
  • a first aspect of the present invention provides a process for the preparation of a crystalline form of eluxadoline characterized by XRPD as depicted in Figure 1 comprising contacting eluxadoline with a solvent.
  • Eluxadoline used for the preparation of the crystalline form of eluxadoline characterized by XRPD as depicted in Figure 1 may be prepared by any method provided in the art, for example, the methods as disclosed U.S. Patent No. 7,741,356.
  • solvents examples include methanol, ethanol, iso-propyl alcohol, n-propyl alcohol, n-butanol, methyl iso-butyl ketone, acetone, dichloromethane, ethyl acetate or a mixture thereof.
  • the preparation of the crystalline form of eluxadoline characterized by XRPD as depicted in Figure 1 is carried out at a temperature of about 35°C to about 75°C.
  • the preparation of crystalline form of eluxadoline characterized by XRPD as depicted in Figure 1 is carried out at a temperature of about 35°C to about 70°C.
  • the preparation of crystalline form of eluxadoline characterized by XRPD as depicted in Figure 1 is carried out at a temperature of about 40°C to about 65°C.
  • the preparation of crystalline form of eluxadoline characterized by XRPD as depicted in Figure 1 is carried out at a temperature of about 45°C to 65°C.
  • the preparation of the crystalline form of eluxadoline characterized by XRPD as depicted in Figure 1 is carried out for about 4 hours to about 24 hours. In an embodiment, the preparation of crystalline form of eluxadoline characterized by XRPD as depicted in Figure 1 is carried out for about 8 hours to about 22 hours. In another embodiment, the preparation of crystalline form of eluxadoline as depicted in Figure 1 is carried out for about 10 hours to about 18 hours. In another embodiment, the preparation of crystalline form of eluxadoline characterized by XRPD as depicted in Figure 1 is carried out for about 12 hours to about 16 hours.
  • the crystalline form of eluxadoline characterized by XRPD as depicted in Figure 1 may optionally be isolated by filtration, decantation, extraction, distillation, evaporation, chromatography, precipitation, concentration, crystallization, centrifugation, and recrystallization.
  • the crystalline form of eluxadoline characterized by XRPD as depicted in Figure 1 may be dried using conventional techniques, for example, drying, drying under vacuum, spray drying, suck drying, air drying, or agitated thin film drying.
  • a second aspect of the present invention provides a process for the preparation of a crystalline form of eluxadoline characterized by XRPD as depicted in Figure 1 comprising:
  • reaction mass ii) heating the reaction mass at 35°C to 70°C followed by optional distillation of the solvent to obtain a reaction mass
  • Eluxadoline used for the preparation of the crystalline form of eluxadoline characterized by XRPD as depicted in Figure 1 may be prepared by any method provided in the art, for example, the methods as disclosed U.S. Patent No. 7,741,356.
  • solvents examples include methanol, ethanol, iso-propyl alcohol, n-propyl alcohol, n-butanol, methyl iso-butyl ketone, acetone, dichloromethane, ethyl acetate or a mixture thereof.
  • the preparation of the crystalline form of eluxadoline characterized by XRPD as depicted in Figure 1 is carried out for about 4 hours to about 24 hours. In an embodiment, the preparation of the crystalline form of eluxadoline characterized by XRPD as depicted in Figure 1 is carried out for about 5 hours to about 22 hours.
  • the preparation of the crystalline form of eluxadoline characterized by XRPD as depicted in Figure 1 is carried out for about 10 hours to about 18 hours. In another embodiment, the preparation of crystalline form of eluxadoline characterized by XRPD as depicted in Figure 1 is carried out for about 12 hours to about 16 hours.
  • reaction mass of step i) is treated with activated carbon.
  • the crystalline form of eluxadoline characterized by XRPD as depicted in Figure 1 may optionally be isolated by filtration, decantation, extraction, distillation, evaporation, chromatography, precipitation, concentration, crystallization, centrifugation, and recrystallization.
  • the crystalline form of eluxadoline characterized by XRPD as depicted in Figure 1 may be dried using conventional techniques, for example, drying, drying under vacuum, spray drying, suck drying, air drying, or agitated thin film drying.
  • a third aspect of the present invention provides a process for the preparation of a crystalline form of eluxadoline characterized by XRPD as depicted in Figure 1 comprising:
  • reaction mass ii) heating the reaction mass followed by partial distillation of the solvent to obtain a reaction mass
  • step iv) storing the crystalline form of step iii) at 25°C to 45°C and relative
  • Eluxadoline used for the preparation of the crystalline form of eluxadoline characterized by XRPD as depicted in Figure 1 may be prepared by any method provided in the art, for example, the methods as disclosed U.S. Patent No. 7,741,356.
  • solvents include methanol, ethanol, iso-propyl alcohol, n-propyl alcohol, n-butanol, methyl iso-butyl ketone, acetone, dichloromethane, ethyl acetate or a mixture thereof.
  • the heating of the reaction mass of step ii) is carried out at a temperature of about 35°C to 85°C. In an embodiment, the heating of the reaction mass of step ii) is carried out at a temperature of about 38°C to about 82°C.
  • the partial distillation of the solvent of step ii) is carried out at a temperature of about 35°C to 85°C. In an embodiment, the partial distillation of the solvent of step ii) is carried out at a temperature of about 38°C to about 82°C.
  • the crystalline form of step iii) is stored for about 1 day to about 7 days. In an embodiment, the crystalline form of step iii) is stored for about 3 days to about 5 days.
  • the crystalline form of eluxadoline characterized by XRPD as depicted in Figure 1 may optionally be isolated by filtration, decantation, extraction, distillation, evaporation, chromatography, precipitation, concentration, crystallization, centrifugation, and recrystallization.
  • the crystalline form of eluxadoline characterized by XRPD as depicted in Figure 1 may be dried using conventional techniques, for example, drying, drying under vacuum, spray drying, suck drying, air drying, or agitated thin film drying.
  • XRPD of the samples was determined by using a PANalytical ® instrument; Model X'pert PRO; Detector: X'celerator ® .
  • Example 1 Preparation of crystalline form of eluxadoline characterized by XRPD as depicted in Figure 1
  • Method A Eluxadoline (10 g) was added to iso-propyl alcohol (300 mL) at 55°C to obtain a reaction mass. The reaction mass was then heated to 60°C to obtain a suspension. The suspension was stirred for 5 hours at 60°C to 66°C, and then cooled to 25°C. The product was filtered, suck dried for 5 minutes and then washed with isopropyl alcohol (20 mL). The solid obtained was suck dried for 5 minutes and then dried under vacuum at 55°C to 60°C for 12 hours to obtain the title compound.
  • Method B Eluxadoline (10 g) was added to n-propyl alcohol (300 mL) at 55°C to obtain a reaction mass. The reaction mass was heated to 60°C to obtain a suspension. The suspension was stirred for 5 hours at 60°C to 65 °C and then cooled to 25 °C. The product was filtered, suck dried for 5 minutes and then washed with n-propyl alcohol (20 mL). The solid obtained was suck dried for 5 minutes and then dried under vacuum at 55°C to 60°C for 12 hours to obtain the title compound.
  • Method C Eluxadoline (10 g) was added to methyl isobutyl ketone (300 mL) at 55°C to obtain a reaction mass. The reaction mass was heated to 60°C to obtain a suspension. The suspension was stirred for 22 hours at 60°C to 65 °C and then cooled to 25 °C. The product was filtered, suck dried for 5 minutes and then washed with methyl isobutyl ketone (20 mL). The solid obtained was suck dried for 5 minutes and then dried under vacuum at 55°C to 60°C for 12 hours to obtain the title compound.
  • Method D Eluxadoline (10 g) was added to ethyl acetate (300 mL) at 55°C to obtain a reaction mass. The reaction mass was heated to 60°C to obtain a suspension. The suspension was stirred for 22 hours at 60°C to 65 °C and then cooled to 25 °C. The product was filtered, suck dried for 5 minutes and then washed with ethyl acetate (20 mL). The solid obtained was suck dried for 5 minutes and then dried under vacuum at 55°C to 60°C for 12 hours to obtain the title compound.
  • Method F Eluxadoline (10 g) was added to n-butanol (300 mL) at 55°C to obtain a reaction mass. The reaction mass was heated to 60°C to obtain a suspension. The suspension was stirred for 22 hours at 60°C to 65 °C and then cooled to 25 °C. The product was filtered, suck dried for 5 minutes and then washed with n-butanol (20 mL). The solid obtained was suck dried for 5 minutes and then dried under vacuum at 55°C to 60°C for 12 hours to obtain the title compound.
  • Method G Eluxadoline (10 g) was added to a mixture of n-propyl alcohol (300 mL) and dichloromethane (400 mL) at 35°C to 38°C to obtain a reaction mass. The reaction mass was heated to 38°C to 40°C to obtain a suspension and then distilled up to a volume of 300 mL at 38°C to 42°C. The suspension was stirred for 3 hours at 50°C to 55°C and then cooled to 25 °C. The product obtained was filtered, and then washed with n-propyl alcohol (20 mL) to obtain a solid. The solid obtained was suck dried for 5 minutes and then dried under vacuum at 55°C to 60°C for 12 hours to obtain the title compound.
  • Method H Eluxadoline (20 g) was added to a mixture of n-propyl alcohol (10 mL) and methanol (800 mL) at 40°C to 45°C and then stirred for 5 minutes to obtain a clear solution. The solution was filtered through Hyflo® and then washed with methanol (40 mL). The filtrate was heated at 60°C to 65 °C and then distilled up to a volume of 200 mL at 60°C to 65 °C to obtain a suspension. The suspension was stirred for 4 hours at 60°C to 65 °C and then cooled to 5°C to 10°C. The product obtained was filtered and then washed with methanol (40 mL) to obtain a solid. The solid obtained was suck dried for 5 minutes and then dried under vacuum at 55°C to 60°C for 12 hours to obtain the title compound.
  • the suspension was stirred for 4 hours to 5 hours at 60°C to 65°C and then cooled to 0°C to 5°C.
  • the product obtained was filtered and then washed with methanol (160 mL) to obtain a solid.
  • the solid was suck dried for 5 minutes and then dried under vacuum at 55°C to 60°C for 15 hours to obtain the title compound.
  • Method I Eluxadoline (10 g) was added to isopropyl alcohol (1200 mL) at 72°C to obtain a reaction mass. The reaction mass was heated to 82°C and then distilled up to a volume of 100 mL at 80°C to 82°C to obtain a suspension. The suspension was stirred for 4 hours at 80°C to 82°C and then cooled to 30°C. The product obtained was filtered, suck dried for 5 minutes and then washed with isopropyl alcohol (20 mL). The solid obtained was suck dried for 5 minutes and then dried under vacuum at 60°C to 65 °C for 12 hours. The solid (2.0 g) was stored at 25 ⁇ 2°C/60 ⁇ 5% RH for 3 days and then further dried under vacuum at 55°C to 60°C for 12 hours to obtain the title compound.

Abstract

La présente invention concerne des procédés de préparation d'une forme cristalline d'éluxadoline.
PCT/IB2018/053134 2017-04-25 2018-05-04 Procédé de préparation d'une forme cristalline d'éluxadoline WO2018198101A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201711014592 2017-04-25
IN201711014592 2017-04-25

Publications (2)

Publication Number Publication Date
WO2018198101A2 true WO2018198101A2 (fr) 2018-11-01
WO2018198101A3 WO2018198101A3 (fr) 2019-05-16

Family

ID=63920194

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2018/053134 WO2018198101A2 (fr) 2017-04-25 2018-05-04 Procédé de préparation d'une forme cristalline d'éluxadoline

Country Status (1)

Country Link
WO (1) WO2018198101A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10314819B2 (en) 2015-07-23 2019-06-11 Teva Pharmaceuticals International Gmbh Solid state forms of Eluxadoline

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101690161B1 (ko) * 2007-07-09 2016-12-27 퓨리엑스 파마슈티컬스, 인코포레이티드 신규한 결정 및 5-（｛［2-아미노-3-（4-카르바모일-2,6-다이메틸-페닐）-프로피오닐］-［1-（4-페닐-1ｈ-이미다졸-2-일）-에틸］-아미노｝-메틸）-2-메톡시-벤조산의 제조 방법
IS2977B (is) * 2015-02-23 2017-07-15 Actavis Group Ptc Ehf. Aðferð til framleiðslu á milliefnum sem eru nytsamleg við nýsmíði á elúxadólíni
US10314819B2 (en) * 2015-07-23 2019-06-11 Teva Pharmaceuticals International Gmbh Solid state forms of Eluxadoline
EP3272741A1 (fr) * 2016-07-21 2018-01-24 Euticals S.P.A. Nouvelles formes cristallines de solvate stable d'eluxadoline
WO2017221213A1 (fr) * 2016-06-23 2017-12-28 Sun Pharmaceutical Industries Limited Méthodes de préparation d'oxazoldinone.
CZ2016548A3 (cs) * 2016-09-07 2018-03-14 Zentiva, K.S. Pevné formy eluxadolinu

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10314819B2 (en) 2015-07-23 2019-06-11 Teva Pharmaceuticals International Gmbh Solid state forms of Eluxadoline

Also Published As

Publication number Publication date
WO2018198101A3 (fr) 2019-05-16

Similar Documents

Publication Publication Date Title
US20080085903A1 (en) Novel crystalline forms of aripiprazole
US20210188896A1 (en) Amine salt of obeticholic acid
WO2015040571A1 (fr) Méthode de préparation de dapagliflozine
WO2020075199A1 (fr) Formes polymorphes de vadadustat
WO2018198101A2 (fr) Procédé de préparation d'une forme cristalline d'éluxadoline
WO2012007487A9 (fr) Procédé de préparation de la forme cristalline ii du fébuxostat
CN102180892A (zh) 一种纯化头孢美唑钠的新方法
WO2016127844A1 (fr) Forme cristalline de l'ipi-145 et son procédé de préparation
WO2011007123A1 (fr) Procédé pour la préparation de levosimendan et intermédiaires destinés à être utilisés dans le procédé
US20150073148A1 (en) Process for the preparation of crystalline vilazodone hydrochloride
US20140378472A1 (en) Amorphous vilazodone hydrochloride, a process for its preparation and pharmaceutical compositions thereof
EA010128B1 (ru) Моногидрохлорид 8-гидрокси-5-[(1r)-1-гидрокси-2-[[(1r)-2-(4-метоксифенил)-1-метилэтил]амино]этил]-2(1h)-хинолинона в кристаллической форме и способ его получения
WO2018185664A1 (fr) Solvates d'éluxadoline
WO2014195977A2 (fr) Nouveaux polymorphes de vismodegib
WO2017081014A1 (fr) Procédé de préparation d'eltrombopag olamine
CN108570045B (zh) 氢溴酸山莨菪碱的晶型、其制备方法、药物组合物
WO2012142983A1 (fr) Sels optiquement actifs de (3ar,4s,6r,6as)-6-amino-2,2-diméthyltétrahydro-3ah- cyclopenta-[d] [1,3]dioxol-4-ol et procédé pour leur préparation
JPH0859517A (ja) 光学分割剤およびそれを用いた光学活性テトラヒドロフランカルボン酸類の製造法
WO2017191620A1 (fr) Forme cristalline d'un sel de sacubitril et procédé pour le préparer
EP3474847B1 (fr) Méthodes de préparation d'oxazoldinone.
CN108976168B (zh) 一种匹伐他汀半钙盐晶型及其制备方法
CN111217781B (zh) 贝前列素-314d晶体和其制备方法
CN106957311B (zh) 雷替曲塞的溶剂化物及其制备方法
EP2499133A2 (fr) Procédé de préparation de la forme cristalline i du sel d'acide l-malique de sunitinib
EP3303345A1 (fr) Co-cristaux d'ertuglifozine et procédé pour les préparer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18791521

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18791521

Country of ref document: EP

Kind code of ref document: A2